(PROGRESS) A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including Glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral BBB, which could then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system.
Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.
- 18 years old and older
- Disease: Brain tumor
- Disease type: Recurrent Glioblastoma Multiforme (GBM)
For additional information about eligibility criteria, please contact the study coordinator :Deborah Sampson
- (352) 273-9000
- Deborah Sampson (firstname.lastname@example.org)
Can be done from home
KeywordsBrain Tumors, Glioblastoma multiforme, Metastatic brain tumor, Glioma, Brain Tumor
Principal InvestigatorDavid D Tran, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.